Kura Oncology stock analysis
Want to see KURA full AI Analyst Report?
Kura Oncology (KURA) Stock Price & Analysis
KURA Stock Chart & Stats
- Day’s Range
- $7.32 - $8.18
- 52-Week Range
- $6.75 - $13.90
- Previous Close
- $7.49
- Volume
- N/A
- Average Volume (3M)
- 2.26M
- Market Cap
- $688.17M
- Enterprise Value
- $495.67M
- Total Cash (Recent Filing)
- $492.10M
- Total Debt (Recent Filing)
- $25.83M
- Price to Earnings (P/E)
- ―
- Beta
- 1.52
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.83
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Adoption
Rapid growth in product revenue, patient starts, and prescriptions indicates strengthening commercial adoption rather than reliance on a single initial launch wave. Expanding utilization can build a larger treated base, improve recurring refill potential, and support a more durable oncology franchise.
Market Position
Holding majority share in the targeted menin inhibitor market suggests meaningful physician preference and an early competitive position in a genetically defined cancer segment. This leadership can support durable prescribing relationships as treatment adoption expands and additional indications develop.
Funding Runway
Substantial liquidity and expected partner payments provide resources to fund commercialization and multiple clinical programs through important development milestones. Greater financing visibility reduces near-term dependence on a single capital raise while allowing continued investment in ziftomenib and darlafarnib.
Bears Say
Persistent Losses
Large operating and net losses show that revenue growth has not yet translated into economic breakeven. Continued investment in commercialization and clinical development may require substantial external funding, while the cost structure could remain a durable constraint on future earnings and cash generation.
Balance-sheet Erosion
The sharp decline in equity has materially reduced financial flexibility and made existing debt more significant relative to the capital base. Higher leverage can constrain strategic choices, increase reliance on future financing, and leave the company less resilient if clinical or commercial execution weakens.
Competitive And Data Risk
Unmatured duration data make the long-term commercial profile less certain, while competing menin inhibitors and reported safety considerations may affect prescribing decisions. Kura must continue demonstrating durable benefit and differentiation to defend share as the therapeutic market develops.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
What is Kura Oncology’s market cap?
When is Kura Oncology’s upcoming earnings report date?
How were Kura Oncology’s earnings last quarter?
Is Kura Oncology overvalued?
Does Kura Oncology pay dividends?
What is Kura Oncology’s EPS estimate?
How many shares outstanding does Kura Oncology have?
What happened to Kura Oncology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kura Oncology?
What is the TipRanks Smart Score and how is it calculated?
Kura Oncology Stock Smart Score
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Troy Wilson
- Employees
- 260
- Website
- kuraoncology.com
- Address
- 4930 Directors Place, San Diego, CA, 92121, US
Kura Oncology (KURA) Earnings & Revenues
KURA Company Deck
KURA Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by 53% sequential COMZIFTI revenue growth, 30% growth in new patient starts, expanding prescribing accounts, majority market share, substantial ASH data visibility, progress toward frontline registration, FDA alignment for a darlafarnib registrational study, and a strengthened funding position. The principal negatives were lower collaboration revenue, immature duration data, ongoing competition, and the fact that just under half of the incident NPM1 population is receiving menin inhibitor therapy. Management presented these items as manageable opportunities or execution priorities rather than material setbacks.
View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |













